Last updated: April 25, 2026
Who supplies efavirenz APIs and key intermediates at scale?
Efavirenz is an established antiretroviral with a mature global supply chain. The manufacturer universe is dominated by API producers that also supply contract manufacturing organizations (CMOs) and directly to branded and generic formulators in multiple geographies (China, India, Europe, and the US).
API and intermediate supply (what the market typically sources)
Efavirenz manufacturing requires: (1) efavirenz API, and (2) key chemical intermediates used in the synthesis route (including substituted anilines and pyrimidine-linked fragments). Market practice is to source either:
- Efavirenz API from an approved API supplier to a finished-dose manufacturer, or
- Custom API/IM packages from CMOs with chemistry-to-site transfer.
Common supplier archetypes
- Direct API manufacturers selling efavirenz API (and sometimes intermediates) under commercial contracts.
- CMOs performing synthesis and/or purification with validated process controls for API supply continuity.
- Regional formulators who buy API and do tablet/capsule manufacture.
- State-backed or quota-influenced supply channels in high-volume procurement markets.
Which companies are known efavirenz API suppliers?
The public record for efavirenz includes recurrent appearances of the same supplier names across generic submissions, procurement listings, and regulator-linked documentation. The most frequently encountered API and generic supply sources include:
API suppliers frequently seen in market
| Supplier |
Typical role in efavirenz supply |
Region |
| Aurobindo Pharma |
API and generic finished-dose supply |
India |
| Cipla |
API and finished-dose supply |
India |
| Hetero Labs (Hetero Drugs) |
API and finished-dose supply |
India |
| Mylan (now Viatris) |
Finished-dose supply; API sourcing |
US/Global |
| Teva |
Finished-dose supply; API sourcing |
Israel/Global |
| Torrent Pharmaceuticals |
Finished-dose supply; API sourcing |
India |
| CordenPharma |
CMO services (manufacturing) for APIs and intermediates in general |
Europe |
| Bharat Biotech-like firms |
Not typical for efavirenz; included here as a caution that many “pharma names” are not API leaders |
Not applicable |
This supplier universe is consistent with how efavirenz is supplied into generic markets: API is procured from established API manufacturers and then finished into tablets or capsules by generic label holders.
How do you qualify efavirenz suppliers for procurement or contracting?
Efavirenz purchasing decisions in pharma are constrained by regulatory status and supply continuity, not by raw vendor capacity. For efavirenz specifically, qualification tends to follow this pattern:
Qualification artifacts typically required
- Regulatory documentation: DMF/CEP references for the API (where available).
- GMP compliance: manufacturing site authorization and inspection history.
- Quality agreements with defined change control (process, equipment, site, raw material source).
- Analytical package: CoA, method validation reports, and impurity profiles.
- Stability data for both API and finished product (as applicable to the contract).
Supply continuity checks
- Multiple-source strategy for API to avoid single-site disruptions.
- Contract language specifying delivery lead times and inventory buffers.
- Traceability and version control for intermediate lots.
What regulatory pathway drives supplier selection for efavirenz?
Efavirenz is an antiretroviral with long-standing generic availability, so supplier selection is often driven by whether the API is positioned to support:
- US ANDA submissions (via DMF linkage for the API), and/or
- EU registrations (via CEP or local dossier support), and/or
- Global tenders (WHO PQ or national program requirements where used).
Implication for business decisions
The API supplier is usually selected because their material can be referenced in regulatory filings and consistently meet impurity specifications across lots. That narrows the vendor list to suppliers with demonstrated dossier readiness and GMP performance.
Where are the procurement bottlenecks likely to occur?
Bottlenecks generally cluster around:
- Intermediates with fewer qualified manufacturers.
- High-impact raw material substitutions (starting materials where impurity patterns shift).
- Batch-to-batch impurity control for mature molecules where regulators expect tight consistency.
Which finished-dose manufacturers commonly source efavirenz API globally?
Finished-dose brands and generics typically buy efavirenz API from one of the commercial API suppliers above and then manufacture tablets or capsules through their own plants or contract manufacturing networks.
Common finished-dose supply channels
| Finished-dose manufacturer (label holder) |
Procurement role |
Typical sourcing approach |
| Cipla |
Generic and established supply |
API procurement from qualified vendors |
| Aurobindo Pharma |
Generic supply |
API sourcing + in-house integration |
| Teva |
Global branded/generic supply |
Multi-source API procurement |
| Viatris |
Generic supply |
Vendor-qualified API inputs |
| Torrent |
Generic supply |
API sourcing under quality agreements |
What to look for in efavirenz CMO services vs. API buy-only contracts?
If you are choosing between buying API directly or contracting the full API manufacturing, the practical differentiator is change control and audit readiness.
API buy-only contract
- You control formulation, stability commitments, and release testing.
- Vendor must deliver consistent impurity profiles and CoAs.
- Your main risk is supplier change notifications and batch variability.
CMO contract
- You reduce dependency on vendor formulation knowledge (if manufacturing is integrated).
- You gain tighter coordination on process parameters and tech-transfer.
- Your main risk becomes audit scope and CMO operational variability.
How should you structure supplier diversification for efavirenz?
For high-reliability antiretroviral procurement, diversification typically means:
- Two qualified API sources with the same quality target profile.
- One CMO backup for emergency supply (if your business model allows it).
- Defined acceptance criteria for each change category (process, impurity limits, intermediate supplier switches).
Key Takeaways
- Efavirenz supply is dominated by a mature group of API manufacturers and CMOs, with India-based producers frequently appearing in the supply chain for both API and finished generics.
- Supplier selection is driven by dossier readiness (DMF/CEP references), GMP compliance, and demonstrated impurity-control consistency across lots.
- Procurement continuity risks concentrate in key intermediates and validated impurity profiles, so contract terms should tightly govern change control and analytical expectations.
- Business models that include diversified sourcing and a CMO backup generally reduce outage risk in mature ARV supply environments.
FAQs
1) Can efavirenz be sourced from multiple countries without regulatory friction?
Yes, but only if the API manufacturer is registered/qualified for the intended filing route and the dossier can be referenced through DMF/CEP-type mechanisms where required.
2) What documents matter most when contracting for efavirenz API?
CoAs plus impurity profiles, GMP site status, and change-control clauses tied to validated analytical methods and acceptance specs.
3) Do finished-dose manufacturers typically make efavirenz API themselves?
Most do not fully vertically integrate. Many buy API from qualified suppliers and focus on formulation, finished dosage control, and regulatory release.
4) Where do quality failures most often show up for mature APIs like efavirenz?
Impurity profile drift and analytical method or specification mismatches caused by intermediate sourcing or process parameter changes.
5) What is the fastest path to dual-source qualification for efavirenz?
Use a pre-defined quality agreement template, require comparative impurity characterization against the incumbent, and lock acceptance limits before tech transfer begins.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMF) and pharmaceutical manufacturing information resources. https://www.fda.gov/drugs/drug-master-files-dmfs
[2] European Medicines Agency. (n.d.). Certificates of Suitability (CEP) and related quality information for medicines. https://www.ema.europa.eu/en/human-regulatory/overview/certificates-suitability-cep
[3] World Health Organization. (n.d.). Prequalification of medicines: information and public assessments. https://extranet.who.int/prequal/
